Glasdegib is under clinical development by Pfizer and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Glasdegib’s likelihood of approval (LoA) and phase transition for Chronic Myelomonocytic Leukemia (CMML) took place on 19 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Glasdegib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Glasdegib (Daurismo) is a anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients aged 75 years and older or who have comorbidities that preclude use of intensive induction chemotherapy.
Glasdegib (PF-04449913) is under development for the treatment of chronic myelomonocytic leukemia, graft versus host disease, and glioblastoma. The drug candidate is administered orally as a tablet. It was also under development for the treatment of hematological malignancies including primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia-myelofibrosis (PET-MF), solid tumor, and myelodysplastic syndrome.
Glasdegib was under development for the treatment of newly diagnosed acute myelocytic leukemia.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Quick View Glasdegib LOA Data
|Highest Development Stage|